

May 4, 2026



# LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), a pharmaceutical company focused on the commercialization of [VIZZ®](#) (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Monday, May 11, 2026, at 4:30 p.m. EDT to report its first quarter 2026 financial results and recent corporate highlights.

To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 1358554. The live webcast can be accessed [here](#) and on the LENZ Therapeutics website at [www.LENZ-tx.com](http://www.LENZ-tx.com) in the Investors & Media section. A replay of the webcast will be available on the Company's website for 30 days following the event.

In addition, company management will host one-on-one meetings at the Bank of America Global Healthcare Conference on May 13–14, 2026, in Las Vegas, Nevada.

## About LENZ Therapeutics

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit [www.VIZZ.com](http://www.VIZZ.com) and [www.LENZ-tx.com](http://www.LENZ-tx.com).

## Contacts:

Dan Chevallard  
LENZ Therapeutics  
[IR@LENZ-Tx.com](mailto:IR@LENZ-Tx.com)



Source: LENZ Therapeutics, Inc.